{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:29:20Z","timestamp":1773804560530,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105411","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:34:30Z","timestamp":1773801270000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Adalimumab as Monotherapy Versus Adalimumab With Methotrexate for Psoriasis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ahmed F","family":"Alanazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A","family":"Almahdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaden O","family":"Alqurashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud","family":"Alassaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz","family":"Almohanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman T","family":"Alayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadi S","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salha","family":"Hakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020749","article-title":"Understanding the intricate pathophysiology of psoriasis and related skin disorders","volume":"26","author":"Orzan OA","year":"2025","unstructured":"Orzan OA, Tutunaru CV, Iano\u0219i SL. Understanding the intricate pathophysiology of psoriasis and related skin disorders. Int J Mol Sci. 2025, 26:749. 10.3390\/ijms26020749","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S506103","article-title":"Psoriasis: unraveling disease mechanisms and advancing pharmacological and nanotechnological treatments","volume":"18","author":"Miao M","year":"2025","unstructured":"Miao M, Yan J, Sun Y, Liu J, Guo S. Psoriasis: unraveling disease mechanisms and advancing pharmacological and nanotechnological treatments. J Inflamm Res. 2025, 18:2045-72. 10.2147\/JIR.S506103","journal-title":"J Inflamm Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S519420","article-title":"Challenges psoriasis and its impact on quality of life: challenges in treatment and management","volume":"15","author":"Ponikowska M","year":"2025","unstructured":"Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis (Auckl). 2025, 15:175-83. 10.2147\/PTT.S519420","journal-title":"Psoriasis (Auckl)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01060-5","article-title":"Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis","volume":"13","author":"Luna PC","year":"2023","unstructured":"Luna PC, Chu CY, Fatani M, Borlenghi C, Adora A, Llamado LQ, Wee J. Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis. Dermatol Ther (Heidelb). 2023, 13:3043-55. 10.1007\/s13555-023-01060-5","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S516109","article-title":"Predictors of quality of life in psoriasis patients: insights from a cross-sectional study","volume":"15","author":"Walniczek P","year":"2025","unstructured":"Walniczek P, Ponikowska M, Kolarczyk EB, Spaleniak P, Mr\u00f3z-Kijowska K, Czapla M, Uchmanowicz I. Predictors of quality of life in psoriasis patients: insights from a cross-sectional study. Psoriasis (Auckl). 2025, 15:163-74. 10.2147\/PTT.S516109","journal-title":"Psoriasis (Auckl)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12267","article-title":"An evolution in switching therapy for psoriasis patients who fail to meet treatment goals","volume":"28","author":"Kerdel F","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015, 28:390-403. 10.1111\/dth.12267","journal-title":"Dermatol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041312","article-title":"Therapeutic advancements in psoriasis and psoriatic arthritis","volume":"14","author":"Yi RC","year":"2025","unstructured":"Yi RC, Akbik M, Smith LR, Klionsky Y, Feldman SR. Therapeutic advancements in psoriasis and psoriatic arthritis. J Clin Med. 2025, 14:1312. 10.3390\/jcm14041312","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/ar4615","article-title":"Adalimumab regulates intracellular TNF\u03b1 production in patients with rheumatoid arthritis","volume":"16","author":"Zamora-Atenza C","year":"2014","unstructured":"Zamora-Atenza C, Diaz-Torne C, Geli C, et al.. Adalimumab regulates intracellular TNF\u03b1 production in patients with rheumatoid arthritis. Arthritis Res Ther. 2014, 16:R153. 10.1186\/ar4615","journal-title":"Arthritis Res Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.134","article-title":"Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis","volume":"31","author":"Jin J","year":"2010","unstructured":"Jin J, Chang Y, Wei W. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol Sin. 2010, 31:1133-40. 10.1038\/aps.2010.134","journal-title":"Acta Pharmacol Sin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:2719. 10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2022.33.40-43","article-title":"Serum levels of tumor necrosis factor - alpha in patients with psoriasis","volume":"34","author":"Ovcina-Kurtovic N","year":"2022","unstructured":"Ovcina-Kurtovic N, Kasumagic-Halilovic E. Serum levels of tumor necrosis factor - alpha in patients with psoriasis. Mater Sociomed. 2022, 34:40-3. 10.5455\/msm.2022.33.40-43","journal-title":"Mater Sociomed"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21037\/jlpm-25-7","article-title":"Personalized methotrexate treatment in immune-mediated inflammatory diseases: a narrative review","volume":"10","author":"Sundaresan J","year":"2025","unstructured":"Sundaresan J, Verstoep LJ, Jansen G, De Jonge R, De Rotte MCFJ, Bulatovi\u0107-\u0106alasan M. Personalized methotrexate treatment in immune-mediated inflammatory diseases: a narrative review. J Lab Precision Med. 2025, 10:13. 10.21037\/jlpm-25-7","journal-title":"J Lab Precision Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski P","year":"2020","unstructured":"Ko\u017ami\u0144ski P, Halik PK, Chesori R, Gniazdowska E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int J Mol Sci. 2020, 21:3483. 10.3390\/ijms21103483","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.10.022","article-title":"Quantifying the effect of methotrexate on adalimumab response in psoriasis by pharmacokinetic-pharmacodynamic modeling","volume":"144","author":"van Huizen A","year":"2024","unstructured":"van Huizen A, Bank P, van der Kraaij G, et al.. Quantifying the effect of methotrexate on adalimumab response in psoriasis by pharmacokinetic-pharmacodynamic modeling. J Invest Dermatol. 2024, 144:794-801.e6. 10.1016\/j.jid.2023.10.022","journal-title":"J Invest Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339:b2535. 10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: an international register of systematic review protocols","volume":"38","author":"Schiavo JH","year":"2019","unstructured":"Schiavo JH. PROSPERO: an international register of systematic review protocols. Med Ref Serv Q. 2019, 38:171-80. 10.1080\/02763869.2019.1588072","journal-title":"Med Ref Serv Q"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184.ch8","article-title":"Assessing risk of bias in included studies","author":"Higgins JP","year":"2008","unstructured":"Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Higgins JP, Green S (ed): John Wiley & Sons, London; 2008. 187-241. 10.1002\/9780470712184.ch8"},{"key":"ref18","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2026). Accessed. February 20, 2026: https:\/\/web.archive.org\/web\/20210716121605id_\/www3.med.unipmn.it\/dispense_ebm\/2009-2010\/Corso%20Perfezionamento%20EBM...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.033","article-title":"Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized\u00a0controlled trial","volume":"142","author":"van der Kraaij G","year":"2022","unstructured":"van der Kraaij G, Busard C, van den Reek J, et al.. Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized\u00a0controlled trial. J Invest Dermatol. 2022, 142:2375-83.e6. 10.1016\/j.jid.2022.01.033","journal-title":"J Invest Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1463","article-title":"Adalimumab monotherapy vs adalimumab with methotrexate for psoriasis","volume":"161","author":"Yiu ZZ","year":"2025","unstructured":"Yiu ZZ, Smith CH, Laws P, Hampton PJ, Griffiths CE, Warren RB. Adalimumab monotherapy vs adalimumab with methotrexate for psoriasis. JAMA Dermatol. 2025, 161:731-8. 10.1001\/jamadermatol.2025.1463","journal-title":"JAMA Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19089","article-title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomized controlled trial","volume":"37","author":"van Huizen AM","year":"2023","unstructured":"van Huizen AM, van der Kraaij GE, Busard CI, et al.. Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomized controlled trial. J Eur Acad Dermatol Venereol. 2023, 37:1815-24. 10.1111\/jdv.19089","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.751483","article-title":"Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice","volume":"24","author":"van den Reek JM","year":"2013","unstructured":"van den Reek JM, van L\u00fcmig PP, Kievit W, Zweegers J, van de Kerkhof PC, Seyger MM, de Jong EM. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat. 2013, 24:361-8. 10.3109\/09546634.2012.751483","journal-title":"J Dermatolog Treat"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20885","article-title":"Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting","volume":"186","author":"Papp KA","year":"2022","unstructured":"Papp KA, Gooderham MJ, Albrecht LE, Raymond MA, Lynde CW. Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting. Br J Dermatol. 2022, 186:726-8. 10.1111\/bjd.20885","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00507-5","article-title":"Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis","volume":"35","author":"Bots SJ","year":"2021","unstructured":"Bots SJ, Parker CE, Brandse JF, et al.. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021, 35:715-33. 10.1007\/s40259-021-00507-5","journal-title":"BioDrugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2024.0114","article-title":"Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13","volume":"32","author":"Kim Y","year":"2025","unstructured":"Kim Y, Choi N, Shin JH, Jo S, Nam B, Kim TH. Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13. J Rheum Dis. 2025, 32:136-44. 10.4078\/jrd.2024.0114","journal-title":"J Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil SK","year":"2021","unstructured":"Mahil SK, Bechman K, Raharja A, et al.. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021, 3:e627-37. 10.1016\/S2665-9913(21)00212-5","journal-title":"Lancet Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115254","article-title":"Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - lessons learned from the COVID-19 pandemic","volume":"165","author":"Wro\u0144ski J","year":"2023","unstructured":"Wro\u0144ski J, Ciechomska M, Kuca-Warnawin E. Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - lessons learned from the COVID-19 pandemic. Biomed Pharmacother. 2023, 165:115254. 10.1016\/j.biopha.2023.115254","journal-title":"Biomed Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104675","article-title":"Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice","volume":"385","author":"Bertolini TB","year":"2023","unstructured":"Bertolini TB, Herzog RW, Kumar SR, et al.. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice. Cell Immunol. 2023, 385:104675. 10.1016\/j.cellimm.2023.104675","journal-title":"Cell Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01621-y","article-title":"Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease","volume":"81","author":"Lenders M","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021, 81:1969-81. 10.1007\/s40265-021-01621-y","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau E","year":"2020","unstructured":"Ducourau E, Rispens T, Samain M, et al.. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020, 6:e001047. 10.1136\/rmdopen-2019-001047","journal-title":"RMD Open"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14926","article-title":"Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials","volume":"34","author":"Xie Y","year":"2021","unstructured":"Xie Y, Liu Y, Liu Y. Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials. Dermatol Ther. 2021, 34:e14926. 10.1111\/dth.14926","journal-title":"Dermatol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15754","article-title":"Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-\u03b1 antagonists versus TNF-\u03b1 antagonists alone in psoriatic patients","volume":"48","author":"Hoffmann JH","year":"2021","unstructured":"Hoffmann JH, Knoop C, Sch\u00e4kel K, Enk AH, Hadaschik EN. Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-\u03b1 antagonists versus TNF-\u03b1 antagonists alone in psoriatic patients. J Dermatol. 2021, 48:835-43. 10.1111\/1346-8138.15754","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471999-efficacy-and-safety-of-adalimumab-as-monotherapy-versus-adalimumab-with-methotrexate-for-psoriasis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:34:31Z","timestamp":1773801271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471999-efficacy-and-safety-of-adalimumab-as-monotherapy-versus-adalimumab-with-methotrexate-for-psoriasis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.105411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}